Upstream Bio, Inc. (UPB) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Upstream Bio, Inc. (UPB) closed at USD 3.42 on 2026-10-14, a change of -86.2 % over the past year, with a market capitalization of USD 184.58M.

Upstream Bio, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Upstream Bio, Inc. key figures

Previous close

USD 3.42 (2026-10-14)

1-year change

-86.2 %

Market cap

USD 184.58M

Enterprise value

USD -75.77M

P/E ratio (trailing)

-1.17

P/E ratio (forward)

-1.20

EPS (trailing)

-2.88

EPS (forward)

-2.80

PEG ratio

n/a

Price to book

0.68

Revenue growth

-17.5 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

7.05

Employees

75

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Upstream Bio, Inc.

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Upstream Bio, Inc. and compare it with other stocks.